Literature DB >> 17544095

Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy.

Frank Siebenhaar, Wolfgang Kühn, Torsten Zuberbier, Marcus Maurer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17544095     DOI： 10.1016/j.jaci.2007.05.011

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  13 in total

Review 1.  Off-Label Uses of Omalizumab.

Authors:  David El-Qutob
Journal:  Clin Rev Allergy Immunol       Date:  2016-02       Impact factor: 8.667

Review 2.  [Childhood-onset mastocytosis].

Authors:  F Siebenhaar; K Weller; U Blume-Peytavi; M Maurer
Journal:  Hautarzt       Date:  2012-02       Impact factor: 0.751

Review 3.  Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosis.

Authors:  Alfonso Quintás-Cardama; Nitin Jain; Srdan Verstovsek
Journal:  Cancer       Date:  2011-06-20       Impact factor: 6.860

Review 4.  Mastocytosis: update on pharmacotherapy and future directions.

Authors:  Juan Carlos Cardet; Cem Akin; Min Jung Lee
Journal:  Expert Opin Pharmacother       Date:  2013-10       Impact factor: 3.889

5.  Bidirectional Transport of IgE by CD23 in the Inner Ear of Patients with Meniere's Disease.

Authors:  Na Zhang; Yafeng Lyu; Jia Guo; Jiahui Liu; Yongdong Song; Zhaomin Fan; Xiaofei Li; Na Li; Daogong Zhang; Haibo Wang
Journal:  J Immunol       Date:  2022-01-19       Impact factor: 5.426

6.  Severe asthma and the omalizumab option.

Authors:  Christopher Wt Miller; Narayanaswamy Krishnaswamy; Chambless Johnston; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2008-05-20

7.  Cutaneous and gastrointestinal symptoms in two patients with systemic mastocytosis successfully treated with omalizumab.

Authors:  Sofie Lieberoth; Simon Francis Thomsen
Journal:  Case Rep Med       Date:  2015-01-28

Review 8.  Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders.

Authors:  P Valent
Journal:  Clin Exp Allergy       Date:  2014-07       Impact factor: 5.018

9.  Anti-immunoglobulin e therapy.

Authors:  Manav Segal; Jeffrey R Stokes; Thomas B Casale
Journal:  World Allergy Organ J       Date:  2008-10       Impact factor: 4.084

10.  Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors:  Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal:  Drug Des Devel Ther       Date:  2014-02-07       Impact factor: 4.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.